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Abstract
Since the discovery of nitric oxide (NO) as a physiological substance produced 
in the endothelium, the impairment of endothelial NO production and reactiv-
ity of the pulmonary vasculature to NO have been described in animal models 
and patients with pulmonary hypertension (PH). The NO synthase-NO-cyclic 
guanosine monophosphate (cGMP) pathway is impaired in pulmonary arterial 
hypertension (PAH), pulmonary veno-occlusive disease (PVOD), pulmonary 
capillary hemangiomatosis (PCH), chronic obstructive pulmonary disease (COPD), 
and idiopathic pulmonary fibrosis (IPF). Pioneering clinicians conceived that NO 
can be administered to the lung by inhalation and used this strategy to treat PH 
in humans and acute hypoxic PH in animal models. Inhaled NO (iNO) selectively 
decreases pulmonary arterial pressure with no changes in systemic arterial pres-
sure. When iNO diffuses into the blood, it is converted to NO3
−, thereby losing 
its vasodilatory effects. NO might then be recycled in hypoxic remote organs, 
where NO3
− and NO2
− are reduced to NO. In the present chapter, the metabolic 
fate of iNO, based on previous air pollution research in Japan, is discussed. Then, 
we describe recent clinical applications of iNO in pediatric patients with various 
diseases, including bronchopulmonary dysplasia (BPD), persistent PH of neonates, 
and congenital diaphragmatic hernia (CDH). We also summarize the role of iNO in 
the catheterization lab, including acute vasoreactivity testing to assess prognosis, 
indications for specific PH therapy, and operability of congenital heart disease.
Keywords: nitric oxide inhalation, pulmonary hypertension, metabolism of nitric 
oxide, nitrate, pediatric, neonate
1. Introduction
In 1980, Furchgott noted that the endothelium produces and releases a vasodila-
tory substance named endothelium-derived relaxing factor (EDRF), which diffuses 
into adjacent vascular smooth muscle cells and results in vascular relaxation [1]. 
In 1987, EDRF was identified as nitric oxide (NO) by Ignarro [2] and Moncada [3]. 
Murad reported the vasodilatory effect of nitroglycerin and NO formation from 
nitroglycerin in 1977 [4]. However, at the time, it was not known that endogenous 




High-temperature combustion accelerates the reaction of oxygen and nitrogen 
in air to generate nitrogen oxides (NOx), such as NO, NO2, and N2O3. A common 
source of NOx is car engines, among which diesel engines have particularly high 
production. NO reacts with O2 to produce NO2, which is more toxic than NO. Thus, 
NOx, including NO, is considered an air pollutant. Accordingly, measuring instru-
ments and NO gas standards with known concentrations are needed to assess 
NO concentrations in air. In addition, NO gas has various industrial applications, 
including uses in the production of chemicals, semiconductors, integrated circuits, 
and memory storage elements and devices. Therefore, measuring instruments 
for NO and the delivery of NO from gas cylinders were developed long before the 
discovery of NO as a physiological substance in the body. NO is now recognized as 
a gas and a physiological substance. Pioneering clinicians determined that “as a gas, 
NO can be administered to the body through the lung.” It was fortunate for these cli-
nicians who first conducted NO inhalation in humans that measuring instruments 
for NO and NO cylinders were available.
The present chapter discusses endogenous NO production in normal and hyper-
tensive pulmonary vasculature, the history of NO inhalation for therapeutic use, 
the fate of inhaled NO (iNO), effects of iNO in remote organs other than the lung, 
and iNO as a therapeutic strategy in pediatrics.
2.  Endogenous NO and its role in the pathogenesis and pathophysiology 
of pulmonary hypertension
NO is primarily synthesized by endothelial NO synthase (eNOS, NOSIII) in 
pulmonary vascular endothelial cells. NO reacts with a receptor, soluble guanylate 
cyclase (sGC), in adjacent smooth muscle cells. Activated sGC produces cGMP, 
which stimulates protein kinase G (PKG) and exerts many physiological effects, 
including pulmonary vascular relaxation. The inhibition of NO production by 
l-NMMA (N-omega-monomethyl-l-arginine, a NOS inhibitor) decreases pulmo-
nary flow in conscious healthy adults [5]. A deficiency in eNOS, but not iNOS or 
neuronal NOS, induces augmented hypoxic pulmonary vasoconstriction and a lack 
of endothelium-dependent vasodilation [6]. These findings support the important 
roles of the eNOS-NO-cyclic guanosine monophosphate (GMP) pathway in main-
taining pulmonary circulation. Alteration of eNOS expression and/or function may 
contribute to decreased NO synthesis in pulmonary hypertension (PH). Human PH 
has many different etiologies. Depending on the pathological state, patients may 
exhibit alterations in the eNOS-NO-cGMP pathway.
2.1 Effects of NO in isolated pulmonary arteries
The effects of NO differ among cell types. NO induces relaxation in vascular 
smooth muscle cells, prevents aggregation and adhesion in platelets, prevents adhe-
sion in leucocytes, and acts as a neurotransmitter in synapses. Thus, NO regulates 
various cell functions. In the vasculature, NO is released from endothelial cells, 
reaches adjacent smooth muscle cells, and causes vascular relaxation, indicating 
that it functions in intercellular signaling. Among the physiological roles of endog-
enous NO, vascular relaxation was discovered first.
In isolated rat main pulmonary arterial rings precontracted with prostaglandin 
F2α (PGF2a), acetylcholine (ACh) induces relaxation in endothelium-preserved 
pulmonary arteries, but not in endothelium-denuded pulmonary arteries, suggest-
ing that the endothelium in pulmonary arteries produces a relaxation-inducing 
substance in response to acetylcholine (Figure 1(a) and (b)).
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In pulmonary arteries isolated from experimental PH models (chronic hypoxic 
PH in rat), the relaxation response to acetylcholine (ACh) is depressed, as observed 
in endothelium-denuded arteries, suggesting that endothelial function is impaired 
in PH arteries. Both ACh- and sodium nitroprusside (SNP, an NO donor)-induced 
relaxations were impaired in pulmonary arteries from rats with chronic hypoxic 
PH, suggesting that NO-induced relaxation is depressed in hypertensive pulmonary 
arteries [7, 8] (Figure 2). However, the magnitude of impairment seems to be 
higher in ACh-induced endothelium-dependent relaxation than in SNP-induced 
endothelium-independent relaxation [7].
Figure 1. 
(a) Acetylcholine induces relaxation in endothelium-preserved pulmonary arterial rings. Pulmonary artery 
rings were obtained from normal control air rats. Rings were suspended in an 20 ml organ bath, and isometric 
tension was measured. Relaxation responses to acetylcholine (Ach) in endothelium-preserved (END+) 
and endothelium-denuded (END-) rings of the extrapulmonary artery were obtained. Endothelium was 
removed by gently rubbing luminal surface by fine stainless wire in endothelium-denuded rings. Rings were 
precontracted with prostaglandin F2a (PGF2a). Relaxation induced by 10
−4 M papaverine (Pap 4) was taken 
as 100%. Bars mean standard error. Relaxation responses to ACh were abolished in the endothelium-denuded 
pulmonary arterial rings, showing that pulmonary vascular endothelium releases vasorelaxation substance 
named endothelium-derived relaxing factor (EDRF). The absence of the endothelium was confirmed by 
scanning electron micrography (b). END−, endothelium-denuded rings; END+, endothelium-preserved rings; 
8, 10−8 mol/L, the same for 7, 6, 5, and 4. (B) Scanning electron micrograph of the endothelium-preserved 
pulmonary artery and endothelium-denuded pulmonary artery. Endothelium was removed by gently rubbing 
luminal surface by fine stainless wire. Left: luminal surface of the endothelium-preserved pulmonary artery. 
Right: luminal surface of the endothelium-denuded pulmonary artery.
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The relaxation responses to SNP are caused by the liberation of NO from SNP. To 
determine the vasodilatory effects of NO directly, a NO solution was made by bub-
bling 10% NO in pure N2 into deoxygenated distilled water. Although depressed, 
the relaxation responses were indeed induced by NO in hypertensive pulmonary 
arteries [7] (Figure 3). Importantly, iNO exhibits selectivity, resulting in vasodila-
tion in pulmonary arteries (Figure 4) when administered by inhalation through 
the trachea. The intravenous injection of NO donors simultaneously decreases both 
pulmonary and systemic arterial pressure.
2.2 Pulmonary arterial hypertension
2.2.1 eNOS in pulmonary arterial hypertension in humans
Although the role of the eNOS-derived NO-related pathway in pulmonary arte-
rial hypertension (PAH) has been determined, its pathophysiology remains unclear. 
eNOS plays a key role in this pathway. Giaid et al. detected decreased eNOS protein 
expression in human lungs with PAH [9]. Additionally, exhaled NO has been found 
to be lower in patients with PAH than in controls [10]. Subsequent studies have 
reported increased eNOS protein expression in plexiform lesions in PAH [11] and 
increased eNOS activity in idiopathic PAH (IPAH) lungs, despite no change in NOS 
expression [12]. The membrane protein caveolin-1 (CAV1) is a crucial negative 
regulator of eNOS activity. The CAV1 expression is decreased in IPAH lungs, which 
might lead to persistent eNOS activation, the accumulation of dysfunctional (i.e., 
uncoupled) eNOS, the formation of peroxynitrite, and the impairment of PKG 
Figure 2. 
The relaxation responses are depressed in isolated pulmonary arterial rings from chronic hypoxic 
pulmonary hypertensive rat. Pulmonary artery rings were obtained from normal control air rats and rats 
exposed to 10 days of hypoxia with chronic hypoxic pulmonary hypertension (PH). Isometric tension was 
measured. Relaxation responses to acetylcholine (ACh) in prostaglandin F2a (PGF2a)-precontracted rings 
of extrapulmonary were recorded. Relaxation induced by 10−4 M papaverine (Pap 4) was taken as 100%. 
Relaxation responses to ACh were depressed in rings from rats with chronic hypoxic PH, showing that the 
release of vasorelaxation substance is impaired in PH rings. Although the relaxation responses to sodium 
nitroprusside (SNP) are impaired in pH rings compared with control, this means that there was a room where 
SNP could cause relaxation in PH rings from chronic hypoxic PH.
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Figure 3. 
NO solution (0.16–0.2 mM NO) caused the relaxation responses in isolated normal and pulmonary 
hypertensive arterial rings. Pulmonary artery rings were obtained from normal control air rats (A), rats 
exposed to 10 days of hypoxia with chronic hypoxic pulmonary hypertension (PH) (B), and rats after 
28 days of recovery in room air from chronic hypoxia (C). NO solution was made by bubbling 10% NO 
through deoxygenated distilled water, which results in 0.16–0.2 mM concentration. Aliquots (0.5 ml) of this 
solution were applied to the organ bath. Papaverine (Pap) was introduced to obtain maximal relaxation. 
Relaxation responses to NO solution to prostaglandin F2a-precontracted rings were recorded. (A) 
NO-induced relaxation in pulmonary artery rings from normal rats. (B) Response to NO was depressed in 
pulmonary artery rings from chronic hypoxic rats. (C) The relaxation response returned to normal after 
28 days of recovery from chronic hypoxic pulmonary hypertension. The result of (B) showed that NO could 
dilate hypertensive pulmonary vascular smooth muscles, although depressed compared to normal.
Figure 4. 
Inhaled NO as selective pulmonary vasodilator in pulmonary hypertensive rats. A pulmonary artery catheter 
was introduced via the right external jugular vein into the pulmonary artery by a closed chest technique. 
Pulmonary arterial pressure(PAP) was recorded with rat fully awake in a pulmonary hypertensive rat (19 
days after the single injection of monocrotaline). About 20 ppm NO inhalation decreased PAP with no change 
of arterial pressure. When NO inhalation was discontinued, the PAP returned to baseline.
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kinase activity via tyrosine nitration [12]. Increased eNOS activity and/or expres-
sion might not be associated with NO production in PAH.
2.2.2 eNOS-NO pathway in animal models of pulmonary arterial hypertension
Animal studies using a monocrotaline (MCT)-induced PAH rat model, which 
is characterized by pulmonary endothelial damage and perivascular inflamma-
tion in the early pathological stage, have shown decreased eNOS expression [13] 
and/or phosphorylated eNOS activity [14] as well as decreases in sGC and 
PKG. Vasodilation induced by ACh, an endothelium-dependent NO-related vaso-
dilator, was also impaired. Another adult rat model of severe PAH with precapillary 
obliterative lesion (SU/Hx model) shows similarities in the pulmonary vascular 
pathology to that of PAH in adults. This SU/Hx model, induced by combined 
SUGEN5416 (a vascular endothelial growth factor receptor II antagonist) and 
exposure to chronic hypoxia, showed a reduction of ACh-induced NO produc-
tion and/or release in pulmonary arteries [15]. Another recent study has reported 
decreased CAV1 expression in the same model [16]. eNOS also translocates from cell 
surface caveolae to cytoplasmic and perinuclear regions in pathological state [17]. 
Consequently, the amount of NO production is decreased. Accordingly, the patho-
genesis and progression of PAH may be partially induced by endothelial dysfunc-
tion associated with suppression of the eNOS-NO-related pathway.
2.2.3 eNOS-NO-cGMP pathway and BMPRII
Genetic variants in the eNOS-NO-cGMP pathway might cause PAH. CAV1 plays 
an important role in NO signaling in PAH. Mutations in CAV1 have been identified 
in PAH [18]. The gene encoding bone morphogenetic protein receptor 2 (BMPRII) 
is frequently mutated in heritable PAH [19, 20] and adult IPAH [19, 21]. BMPRII 
is a member of the transforming growth factor (TGF)-β receptor superfamily, 
localized to caveolae, and interacts with CAV1 in vascular smooth muscle cells 
[22, 23]. Recent studies have demonstrated that BMPRII deficiency promotes 
SRC-dependent caveolar trafficking defects [24]. In addition, CAV1-deficient mice 
have shown reduced BMPRII expression after exposure to chronic hypoxia [16]. In 
MCT-treated pulmonary arterial endothelial cells, BMPRII was increasingly trapped 
intracellularly together with increased trapping CAV1 and eNOS. These results sug-
gest that NO-cGMP-related dysfunction and BMPRII deficiency are closely related 
to and play a significant role in the pathogenesis of PAH.
2.3  Pulmonary veno-occlusive disease and pulmonary capillary 
hemangiomatosis
Pulmonary veno-occlusive disease (PVOD), classified as a PAH subgroup, is 
inextricably associated with pulmonary capillary hemangiomatosis (PCH) [25]. 
Pulmonary vascular lesions in this condition are mainly detected in postcapillary 
venules and veins but are also found in pulmonary capillaries and arteries [25]. The 
pathogenesis is heterogeneous and poorly understood [25]. These are rare diseases, 
and few studies have focused on the pathogenesis and pathophysiology. Kradin 
et al. reported that eNOS expression in abnormal capillary lesions is significantly 
decreased in patients with PCH with pulmonary vascular remodeling and con-
comitant pulmonary hypertension and is minimally decreased or not decreased 
in patients without pulmonary vascular remodeling [26]. These results suggest 
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that the alteration of eNOS expression is associated with the pathogenesis of these 
complicated conditions. Further experiments are necessary to determine the precise 
role of the eNOS-NO-cGMP pathway in PVOD/PCH.
Biallelic mutations in eukaryotic translation initiation factor 2α kinase 4 
(EIF2AK4) have been identified in familial and idiopathic PVOD/PCH. EIF2AK4 
encodes general control nonderepressible 2 (GCN2) [27]. The most common 
experimental models of these conditions are mitomycin C (MMC)-treated rats and 
mice [28]. Interestingly, MMC dose dependently induces pulmonary GCN2 deple-
tion [28]. EIF2AK4 mutations are also found in sporadic PVOD/PCH [27]. Mutation 
carriers have distinct histological features, including strong muscular hyperplasia of 
the interlobular septal vein as well as arterial severe intimal fibrosis [29]. EIF2AK4 
is activated by amino acid depletion. Because l-arginine, a substrate of NOS, is 
depleted during NO production, EIF2AK4 activation can be induced by eNOS activ-
ity associated with l-arginine depletion.
2.4 Lung disease-related and/or alveolar hypoxia-induced pH
The pathophysiologic features of lung diseases include chronic obstructive 
pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) and mixed 
pathologic diseases, including combined pulmonary fibrosis and emphysema. All 
involve alveolar hypoxia and subsequent hypoxic pulmonary vasoconstriction. 
eNOS expression is upregulated in acute hypoxia in rat lungs [30]. eNOS expression 
increases in a time-dependent manner in rats during the development of hypoxia-
induced PH [31–33], while eNOS activity is impaired [34]. The production of tetra-
hydrobiopterin (BH4), an obligatory cofactor for generating the active dimer form 
of eNOS, was altered in hypoxic conditions [34]. An imbalance between BH4 and 
dihydrobiopterin (BH2) may cause eNOS uncoupling and inactive monomer forma-
tion [34]. Several studies have reported decreased eNOS expression and/or activity 
in patients with COPD [35, 36], with severity of endothelial dysfunction correlated 
with degree of airflow obstruction [36]. eNOS is also absent in pulmonary arteries 
of patients with IPF [37]. As the histological features of this disease differ from 
those of COPD, the pathogenesis of IPF-induced PH may include a multifactorial 
and complex process involving proinflammatory cytokines and growth factors.
3. Inhaled nitric oxide
3.1 Inhaled NO as a selective pulmonary vasodilator
In 1988, at the international conference of the American Thoracic Society, 
Higenbottam presented his team’s paper titled “Inhaled endothelium-derived relax-
ing factor (EDRF) in primary pulmonary hypertension (PPH),” including the first 
description of NO inhalation in humans with pulmonary arterial hypertension for 
laboratory use [38]. In 1991, Lancet published the study [39], showing that 40 ppm 
NO inhalation selectively reduces PAP, with no changes in systemic pressure. 
Frostell et al. also showed that inhaled NO (5–80 ppm) causes selective pulmonary 
arterial dilatation, without changes in systemic arterial pressure in sheep [40], 
where PAP elevation was induced by hypoxic pulmonary vasoconstriction. Both 
research groups referenced the studies by Yoshida, Kasama, and Kitabatake about 
the metabolic fate of iNO [41, 42] because toxicity and retention in the human body 
should be minimal. NO has been a focus in air pollution research and thus provides 
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a basis for work by clinicians evaluating NO inhalation in humans. In rats with 
chronic hypoxia- and MCT-induced PH, iNO results in a decrease in PAP with no 
changes in systemic arterial pressure [43–45] (Figure 4).
3.2 Clinical effects of iNO
iNO dilates the pulmonary vasculature by NO combining with guanylate 
cyclase Fe in pulmonary vascular smooth muscle cells. Most NO diffuses into the 
blood at alveoli, where it reacts with the Fe of oxygenated hemoglobin (oxy-Hb, 
O2Hb, O2Hb(Fe
2+)) in red blood cells and is converted to NO3
−. When NO reacts 
with oxy-Hb Fe2+ or combines with the Fe2+ of deoxygenated Hb (deoxy-Hb, 
deoxy-Hb(Fe2+)) in red blood cells, iNO does not have direct vasodilatory effects 
because it reacts or combines with Hb Fe2+ and becomes unable to combine with 
guanylate cyclase Fe of smooth muscle cells in systemic arteries. Thus, iNO is 
a selective pulmonary vasodilator, causing decreased PAP with no changes in 
systemic pressure (Figure 4).
The clinical use of NO inhalation is aimed at inducing selective pulmonary arte-
rial dilation and treating PH and right ventricular failure. NO inhalation is also used 
to test pulmonary vascular reactivity in catheterization labs, which will be discussed 
in the last section of this chapter. Improved arterial oxygenation is also expected in 
patients with high intrapulmonary shunting [46]. Thus, the main target of iNO is 
lung and pulmonary circulation. In addition, iNO effects on remote organs, such as 
the kidney [47], liver [48, 49], heart [50], and muscle [51], have been investigated, 
with iNO shown to ameliorate inflammation and ischemia-reperfusion injury.
3.3 Substances that react with NO
NO reacts or combines with transition metal ions, such as thiols (–SH, –SS–, and 
HS–). Many enzymes and substances involved in regulating cell function include 
in their structure Fe, a transitional metal, thus suggesting its importance as an NO 
target. Because hemoglobin (Hb) and guanylate cyclase contain heme, which includes 
Fe in its structure, NO reacts or combines with Hb and guanylate cyclase. NO also 
combines with enzymes containing Fe–S in their structure, and combined NO (nitra-
tion) and Fe–S can prevent enzymatic activity. High concentrations of NO induce cell 
damage, which presumably result from this enzymatic dysfunction. Thus, NO is a 
double-edged sword. Although an appropriate amount is important for regulating cell 
function, an excess dysregulates cell function and causes damage.
RS–NO is a complex of SH– and NO. Nitrosothiol is a thionitrite includ-
ing S-nitroso-albumin, where NO combines with cysteine, a component of 
albumin. –SH is a component of amino acids, peptides, and proteins. NO binds 
to –SH, forming S-nitrosothiol, 96% of which is S-nitrosoprotein. About 82% of 
S-nitrosoprotein is serum S-nitrosoalbumin. Thus, endogenous NO circulates in the 
form of S-nitrosoalbumin [52].
NO targets are transition metal ions, oxygen, nucleophilic centers (thiols, 
amides, carboxyls, and hydroxyls), and free radicals. iNO targets are (Figure 5) also 
transition metal ions, namely, in the guanylate cyclase Fe, Hb Fe, iron-sulfur (Fe-S) 
center. Other targets include oxygen (gaseous oxygen in the airway and alveoli), 
dissolved oxygen in the tissue and body fluids, the nucleophilic center of organic 
compounds (–S–S– and –SH), and free radicals (reactive oxygen species produced 
in leucocytes and macrophages). Among these substances that react with iNO, The 
main target of an approved medical iNO gas is guanylate cyclase Fe in pulmonary 
vascular smooth muscle cells.
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3.4 Metabolic fate of iNO
3.4.1 Oxidation and reduction of NO
Oxidation refers to electron loss and reduction to electron gain. Reducing agents 
release electrons, whereas oxidizing agents receive electrons. The term redox is a 
combination of “reduction and oxidation reaction.” Reduction and oxygenation 
occur simultaneously so that when a reducing agent is oxidized, an oxidizing agent 
is also reduced. Nitrogen monoxides involve an array of species: NO+ (nitrosonium), 
NO·, and NO− (nitroxyl anion) [53]. Among these, NO· has a single electron, and its 
removal forms NO+, whereas its addition yields NO−. NO· is electrically neutral, which 
contributes to its free diffusibility in aqueous medium and across cell membranes.
The main NO· targets are oxygen and transition metal ions. The various redox 
forms of oxygen, such as superoxide (O2
−) and (di)oxygen, are candidates in both 
the gas phase and aqueous solution. Metalloproteins, such as heme-containing 
protein and non-heme-containing protein, and iron-sulfur clusters also react with 
NO·.
iNO reacts with oxy-Hb. NO oxidizes oxy-Hb to form MetHb. In other words, 
MetHb is oxidized oxy-Hb. Oxidized iron (MetHb) species do not catch NO, and 
iNO during cardiopulmonary bypass (CPB) decreases acute kidney injury [47]:
  O 2 Hb ( Fe 
2+ ) 
 [oxy‐Hb] 
 + NO →  Hb ( Fe 3+ ) 
 [MetHb] 
 +  NO 3 
−
                  (1)
3.4.2 NO and Hb
NO reacts or combines with Hb in three ways: (1) NO combines with in the 
heme Fe to form NOHb (nitrosyl Hb), a metal nitrosyl species; (2) NO− combines 
Figure 5. 
The substances in the lung to react or combine with iNO. NO reacts with Fe in the guanylate cyclase (GC) and 
induces cyclic GMP and subsequent pulmonary vascular relaxation; NO reacts with Fe2+ in O2Hb and forms 
MetHb and NO3
−; NO and Fe2+ in deoxy-Hb combine in NOHb; NO and O2 combine in NO2; NO and O2- 
combine in ONOO-; NO and OH- combine in NO2-; NO and thiol (sulfhydryl group, -SH group), amine, and 
iron-sulfur (Fe-S) center combine in nitrosothiol, nitrosamine, and Fe-S NO, respectively. RSH is a compound 
including SH group. S-nitro-Hb is combination of NO and SH in the cysteine in the Hb beta subunit. Reactive 
oxygen species (O2
−, OH−) are produced in leucocytes and macrophages.
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with amines in Hb to form S-nitroso-Hb, a nitrosamine, where NO combines with 
cysteine in the beta subunit of Hb; and (3) O− or NO+ combines with the sulfhy-
dryl center (-SH) in Hb. NO reacts with oxy-Hb and combines with deoxy-Hb. 
If NO reacts with oxy-Hb (Fe2+), MetHb (Fe3+) and nitrate (NO3
−) are formed. If 
NO combines with deoxy-Hb (Fe2+), NOHb (Fe2+) is formed, after which NOHb 
(Fe2+) reacts with O2 to form MetHb (Fe
3+) and NO3
−. MetHb (Fe3+) is reduced to 
deoxy-Hb (Fe2+) by MetHb reductase. The depletion of MetHb reductase or high 
production of MetHb causes methemoglobinemia. NO3
− is excreted in the urine 
(Figures 6, 7).
In an in vitro experiment, Wennmalm [54] incubated NO with arterial and 




. The reaction of NO 
with O2Hb was rapid in the arterial blood (oxygen saturation 94–99%). NOHb was 
low in arterial blood and high in venous blood (oxygen saturation 36–86%). These 
results suggest that O2Hb (oxy-Hb) gives O2 to NO making NO3
−. In contrast, 
deoxy-Hb directly combines with NO making NOHb in the absence of oxy-Hb 
(i.e., in the presence of deoxy-Hb). The NO and oxy-Hb reaction is completed in 
100 ms [55].
3.4.3 NOHb
Nakajima and Oda have shown that the NOHb concentration is 0.13% in the 
blood during 20 min of 10 ppm NO inhalation [56]. This low concentration suggests 
the rapid turnover of NOHb, in which NOHb is presumably an intermediate in the 
conversion from NO to NO2
− and NO3
−.




− is added to human blood, NO3
− changes are detected within 
10 min [57]. The intravenous injection of sodium nitrite to rabbits results in the 
rapid disappearance of NO2
−. After the intratracheal injection of 13NO2
−, 70% of 
13NO2
− changed to 13NO3
−, and 26% remained as 13NO2
− [58]. These observations 
suggest that NO2
− is converted to NO3
− in red blood cells [59]. NO2
− and NO3
− are 
stable and unchanged in plasma without red blood cells.
Figure 6. 
Reaction of NO with Hb. NO reacts with Fe2+ of oxy-Hb making MetHb and NO3
− and combines with 
deoxy-Hb making NOHb. NOHb reacts with O2 making MetHb and NO3
−.
11
Endogenous and Inhaled Nitric Oxide for the Treatment of Pulmonary Hypertension
DOI: http://dx.doi.org/10.5772/intechopen.89381
3.4.5 No retention of iNO in the body
A clear understanding of the fate of iNO is critical for its clinical use in humans. 
As previously mentioned, the metabolic fate of iNO was examined in the early 
1980s, and it was found that retention of iNO in the body was lacking (Figure 7).
An inhalation study of 15NO in rats investigated the metabolism of iNO. In the 
carcasses, 1.6% of total inhaled 15N was detected, similar to the level of natural 
15N. This result suggests that iNO largely does not remain in the body. About 55% of 
total inhaled 15N was recovered in urine [41, 42], including 45% as nitrates and 10% 
as urea (Figure 7). About 10% of total inhaled 15N was recovered as undetermined 
nitrogen compounds in feces. The remaining 35% was not recovered but is assumed 
to be N2 produced from the reduction of NO3
− → NO2
− → N2 by stomach flora.
3.5 iNO effects in remote organs
During cardiopulmonary bypass(CPB), hemolysis causes an increase in Hb 
plasma concentration due to the destruction of red blood cells. Hb includes oxy-Hb 
and deoxy-Hb. Oxy-Hb causes vasoconstriction, which is partly due to the depletion 
of NO available to induce vascular smooth muscle relaxation. NO is produced in and 
released from endothelial cells, some of which reaches adjacent vascular smooth 
muscles, causing vasorelaxation, and some of which diffuses into the plasma. If the 
amount of oxy-Hb in the plasma increases, the binding of NO to oxy-Hb increases, 
resulting in less NO reaching adjacent smooth muscle cells. Thus, the presence of 
large amounts of oxy-Hb might decrease NO availability in vascular smooth muscle 
cells (Figure 8).
Figure 7. 
Metabolic fate of NO. Almost all inhaled NO is converted to NO3
−. Forty-five percent of NO3
− is excreted in 
urine; 10% is changed to nitrogen compound except NO3
− and NO2
− and excreted in feces; 10% is changed to 
urea through the digestive tract and liver and excreted in urine. The rest will be changed to N2 in the stomach 
and discharged outside of the body.
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Acute kidney injury is a common complication after cardiac surgery with pro-
longed CPB. Because oxygen tension is high during CPB, plasma oxy-Hb exhibits 
substantial hemolysis, causing vasoconstriction in the kidney. Recently, NO was 
demonstrated to decrease the occurrence of acute kidney injury and chronic kidney 
disease 1 year postoperatively [47]. NO inhalation at 80 ppm was started at the onset 
of CPB via a CPB machine and was continued after CPB via a mechanical ventilator 
for 24 h or less if patients were ready to be extubated early. Under NO inhalation, 
oxy-Hb was converted to MetHb, which recovered NO availability to vascular smooth 
muscle cells due to the decrease in oxy-Hb. Thus, exogenous NO inhalation might 
increase endogenous NO availability to counteract renal vasoconstriction during CPB.
In brief, the reduction of nitrite and nitrate produces NO (Figure 9). Nitrite is 
reduced by deoxy-Hb, respiratory chain enzymes, xanthine oxidoreductase, deoxy-
genated myoglobin, and protons, facilitating the transfer of protons to NO2
− and 
thereby producing NO. These reactions are intensified under acidic and hypoxic 
states. After iNO is converted to NO2
− and NO3
−, NO can be recycled from nitrite 
and used to protect organs from ischemia-reperfusion injury [48, 51].
In liver transplantation, the inhalation of 80 ppm NO until reperfusion amelio-
rates apoptosis, attenuated increases of liver enzymes, and enhanced the recovery 
of coagulation factors [48].
In orthopedic knee surgery, NO inhalation prevented increases in the adhesion 
molecule expression on granulocytes, plasma selectin levels, and NF-κB expres-
sion in quadriceps muscles [51]. NO inhalation was started before the tourniquet 
application and was continued during reperfusion until the completion of surgery.
Figure 8. 
NO formed in the endothelium is scavenged by plasma oxygenated Hb. (A) NO produced in the endothelium 
diffuses into adjacent smooth muscle cells and binds with guanylate cyclase. (B) If O2Hb (Fe
2+) increases, NO 
produced in the endothelium diffuses into the blood and scavenged by O2Hb (Fe
2+), decreasing the amount of 
NO diffused into smooth muscle cells. (C) If O2 Hb(Fe
2+) is converted to MetHb(Fe3+) by NO inhalation, NO 
is not scavenged, which recovers the amount of NO diffusing to the smooth muscle side.
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4. Update on the clinical application of iNO in pediatric patients
After NO was identified as an endothelial cell-derived relaxation factor and fol-
lowing preclinical studies, iNO therapy has been studied extensively in multicenter 
randomized trials as well as in early pilot studies of infants with severe hypoxemia 
associated with PH or infants with congenital diaphragmatic hernia (CDH) [60]. 
These studies have demonstrated improved oxygenation and reduction in the 
need for extracorporeal membrane oxygenation (ECMO) therapy, leading to the 
approval of iNO therapy by the Food and Drug Administration for use in patients 
at >34-week gestation with hypoxemic respiratory failure and persistent PH of the 
newborn (PPHN). Over the last two decades, the discussion of its application has 
been extended to premature infants and acute pulmonary vascular response testing 
to assess indications for specific pulmonary vasodilator therapy for patients with 
PAH or operability for children with congenital heart disease.
4.1  Role of inhaled NO in the prevention of bronchopulmonary dysplasia in 
premature newborns
Bronchopulmonary dysplasia (BPD), which is characterized by impaired 
pulmonary development resulting from insults affecting the immature lung, 
including inflammation, hyperoxia, and mechanical ventilation, is associated with 
high mortality and adverse long-term neurological and respiratory outcomes in 
infants born very preterm. Although the effectiveness of iNO for the treatment of 
PPHN is largely due to its function as a selective pulmonary vasodilator, labora-
tory observations also suggest other important biological effects of NO, such as 
roles in decreasing lung inflammation (e.g., lung vascular protein leak; pulmonary 
neutrophil accumulation) [61], reducing oxidant stress [62], decreasing pulmonary 
vascular cell proliferation [63], and enhancing alveolarization and lung growth 
[64–66]. These observations have led to investigations into the use of iNO to 
prevent the development of BPD in premature newborns. In an initial randomized, 
Figure 9. 
Recycle of NO from nitrite and nitrate. Nitrate is reduced to nitrite, and subsequent reduction of nitrite forms 
NO. Reducing substances are deoxy-Hb [Hb(Fe2+)], myoglobin [Mb(Fe2+)], xanthine oxidase, hydrogen ion 
(H+), and cytochrome enzymes (Fe
2+). NO2
− is reduced by deoxy-Hb(Fe2+) to NO showing stoichiometric 
relation. Please count the number of O before and after the reduction responses.
Endothelial Dysfunction
14
placebo-controlled study in a single center, 7 days of iNO prevented chronic lung 
disease in premature infants [67]. Despite promising findings in some subsequent 
studies showing a reduction in BPD in premature newborns [68, 69], later trials 
did not confirm the beneficial effects [70]. Meta-analyses of these studies have not 
found evidence for a net improvement in either chronic lung disease or develop-
mental sequelae [71], leading to the conclusion by the National Institutes of Health 
Consensus Development Conference [72] and the American Academy of Pediatrics 
Committee on the Fetus and Newborn [73] that the use of iNO to prevent BPD is 
not supported by available evidence [74].
4.2 iNO for the treatment of severe pulmonary hypertension in preterm infants
In addition to the use of iNO for BPD prevention, its use in preterm infants 
for acute management of severe hypoxemic respiratory failure has been dis-
cussed. Several case series have described responses to iNO in premature new-
borns with PPHN associated with prolonged oligohydramnios and pulmonary 
hypoplasia. Chock et al. evaluated a subset of 12 premature newborns enrolled in 
the Preemie Inhaled Nitric Oxide Trial with pulmonary hypoplasia after preterm 
premature rupture of membranes (PPROM) [75]. Six infants were treated with 
iNO with a mortality rate of 33% compared with 67% mortality for six infants 
in the placebo control group. Shah and Kluckow described outcomes for infants 
with PPROM and reported that survival improved from 62 to 90% after the 
introduction of iNO and high-frequency oscillatory ventilation [76]. Semberova 
et al. reported a series of 22 premature infants with a history of PPROM, pul-
monary hypoplasia, and PPHN who were treated with iNO, with a survival rate 
of 86% [77]. Thus, iNO therapy may have important benefits in subgroups of 
preterm infants with severe PH, especially in patients with oligohydramnios 
and lung hypoplasia. Further studies of the precise effects of iNO in premature 
neonates are needed.
4.3 Role of iNO in newborns with congenital diaphragmatic hernia
iNO in neonates with CDH has been evaluated in three randomized trials 
[78–80]. Finer and Barrington performed a Cochrane Review [81] of the use of iNO 
for respiratory failure in infants born at or near term. They concluded that while 
iNO might transiently improve oxygenation, its use is not recommended for infants 
with CDH because the risks of a composite of either death or ECMO are similar to 
or worse than those of controls [82].
Based on this evidence, iNO cannot be recommended for the routine treat-
ment of PH in patients with CDH. However, iNO continues to be regularly used 
for CDH. Indeed, iNO was used at some point during preoperative stabilization 
in 36% (191/526) of infants with CDH from the population-based CAPSNet 
database. The ability of iNO to improve oxygenation and reduce the need for 
ECMO in non-CDH patients with PH explains its continued use in patients with 
CDH. The lack of a response to pulmonary vasodilators in CDH is speculated to 
be likely due to left atrial/pulmonary vein hypertension rather than to functional 
changes in the pulmonary arterial vasculature [83]. A recent study suggests that 
the response to pulmonary vasodilators in neonates with CDH may be limited 
by the severity of left ventricular (LV) dysfunction and/or hypoplasia, which 
impairs LV filling. Careful echocardiographic assessment, therefore, may guide 
treatment by identifying patients who may benefit from pulmonary vasodilators, 
including iNO [83].
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4.3.1  Acute vasoreactivity testing to assess prognosis and indications for specific PH 
therapy
The prognosis of children with PAH has improved in the past decade owing 
to new therapeutic agents and aggressive treatment strategies [84]. In idiopathic 
or heritable PAH (I/H-PAH), acute vasodilator testing (AVT) is recommended 
to identify patients who have a good long-term prognosis when treated with a 
long-term calcium channel blocker (CCB), accounting for 7–37% of children with 
PAH. For example, a >20% decrease in PAP or pulmonary vascular resistance (PVR) 
to inhaled NO accurately predicts a subsequent response to oral vasodilators, such 
as nifedipine. To identify such patients, the Sitbon criteria for positive AVT, as 
defined by a decrease in mean PAP by ≥10 mmHg to a value of <40 mmHg with an 
increased or unchanged cardiac output, is commonly used in adult I/H-PAH [85]. 
The Sitbon criteria can also be used to identify children who are expected to show a 
sustained response to CCB therapy [86]. Based on these data, the use of the Sitbon 
criteria is advised for AVT in children. Because only half of adult responders have 
a long-term hemodynamic and clinical improvement in response to CCB therapy, 
close long-term follow-up is required [87].
4.3.2  Acute vasoreactivity testing to assess operability of PAH associated with 
congenital heart disease
AVT is also used to assess operability in children with PAH associated with a 
systemic-to-pulmonary shunt [87, 88]. Although pulmonary vasodilators other than 
iNO, such as inhaled iloprost or other orally or intravenously administered compounds 
(e.g., sildenafil and treprostinil), can be used for AVT, iNO ± oxygen is recommended 
[87]. The hemodynamic change that defines a positive response to AVT in PAH 
Figure 10. 
Acute vasoreactivity testingto assess operability. AVT is also used to assess operability in children with PAH 
associated with a systemic-to-pulmonary shunt [87, 88]. (Figure10, unpublished). A 5-month-old infant 
with Down syndrome and an atrial septal defect was evaluated for operability by acute vasoreactivity testing 
using inhaled nitric oxide. Pulmonary hemodynamic parameters at baseline, including pulmonary arterial 
pressure (76/29/49 mmHg), pulmonary vascular resistance index (6.7 Wood units m2), the ratio of pulmonary 
to systemic vascular resistance (0.45), and the ratio of pulmonary to systemic blood flow (1.74), are changed 
to 60/14/32 mmHg, 3.14 Wood units m2, 0.20, and 2.2 after nitric oxide inhalation, respectively. The patient 
underwent surgical closure of the shunt, and no postoperative pulmonary hypertension was observed. NO, 
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associated with a shunt (a ratio of pulmonary to systemic blood flow >1.5) for children 
should be a >20% decrease in PVR index and a ratio of pulmonary to systemic vas-
cular resistance with respective final values of <6 Wood units m2 and <0.3. However, 
specific criteria for defining a positive AVT response that predicts the reversal of PAH 
and good long-term prognosis have not been described. The pediatric task force of the 
Sixth World Symposium on Pulmonary Hypertension agreed on a general guidance 
for assessing operability in CHD-PAH but emphasized that the long-term impact of 
defect closure in the presence of PAH with increased PVR is unknown [84].
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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